Document is current
Any future updates will be listed below
-
Authors
Zhang, Qi
Ju, Bin
Ge, Jiwan https://orcid.org/0000-0001-9366-1470
Chan, Jasper Fuk-Woo https://orcid.org/0000-0001-6336-6657
Cheng, Lin
Wang, Ruoke https://orcid.org/0000-0002-8040-7913
Huang, Weijin https://orcid.org/0000-0002-4246-8889
Fang, Mengqi
Chen, Peng https://orcid.org/0000-0002-9041-8392
Zhou, Bing
Song, Shuo
Shan, Sisi https://orcid.org/0000-0002-7184-6818
Yan, Baohua
Zhang, Senyan https://orcid.org/0000-0003-1703-3848
Ge, Xiangyang
Yu, Jiazhen
Zhao, Juanjuan
Wang, Haiyan
Liu, Li https://orcid.org/0000-0003-2566-7357
Lv, Qining
Fu, Lili
Shi, Xuanling
Yuen, Kwok Yung https://orcid.org/0000-0002-2083-1552
Liu, Lei
Wang, Youchun https://orcid.org/0000-0001-9769-5141
Chen, Zhiwei https://orcid.org/0000-0002-4511-2888
Zhang, Linqi https://orcid.org/0000-0003-4931-509X
Wang, Xinquan https://orcid.org/0000-0003-3136-8070
Zhang, Zheng https://orcid.org/0000-0002-3544-1389
-
Funding
Funding for this research was provided by:
National Science Fund for Distinguished Young Scholars
- License Information
-
More Information
Article History
Received: 25 November 2020
Accepted: 7 June 2021
First Online: 9 July 2021
Competing interests
: The authors declare the following competing interests: Patent applications have been filed on monoclonal antibodies targeting SARS-CoV-2 (patent application number: PCT/CN2020/108718; patent applicants: The Third People’s Hospital of Shenzhen and Tsinghua University). Q.Z., B.J., X.S. Lei Liu, L.Z., and Z.Z. are the inventors. All other authors declare no competing interests.
